DOCSLIB.ORG

Pediatric News Nursing Woman

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pediatric News Nursing Woman 16 Infectious Diseases P EDIATRIC N EWS • July 2008 Virtually All Pediatricians Follow Tdap Guidelines BY ROBERT FINN recommending Tdap were medical spe- theria toxoids (Td) with Tdap. The com- for pediatricians and 53% for family physi- San Francisco Bureau cialty (pediatrics vs. family practice) and mittee suggested age 11-12 years as the cians, Dr. Dempsey reported in a poster whether the physician stocked the com- preferred age for Tdap vaccination, and presentation at the joint meeting of the H ONOLULU — One year after the Cen- bined tetanus toxoid, reduced diphtheria recommended the catch-up vaccination of Pediatric Academic Societies. ters for Disease Control and Prevention is- toxoid, and acellular pertussis vaccine adolescents aged 13-18 years. Survey results showed that 68% of pedi- sued new recommendations on vaccinat- (Tdap) in their offices, wrote Dr. Amanda The study involved a mail-based survey atricians were significantly more likely than ing adolescents against pertussis, 96% of F. Dempsey of the University of Michigan, of a national sample of 725 pediatricians were family physicians to have adolescent pediatricians but only 75% of family physi- Ann Arbor, and her colleagues. and 725 family physicians drawn random- patient volumes above 25%, although most cians were recommending the vaccine rou- In March 2006, the CDC’s Advisory ly from the American Medical Associa- respondents reported that at least 10% of tinely, according to a mail-based survey. Committee on Immunization Practices tion’s Physician Masterfile. The survey their patients were adolescents. In a multivariate analysis, the only two (ACIP) issued recommendations on re- was conducted between January and On the question of Tdap recommenda- variables independently associated with placing the adolescent tetanus and diph- March 2007. The response rates were 68% tion patterns for 11- to 12-year-old patients, 96% of pediatricians said that they rou- tinely issued such recommendations, 3% ® of 0.6, 2.0, and 6.0 mg/kg/day, up to 150 times the maximal daily human DIFFERIN (adapalene) Cream, 0.1% Incidence of Local Cutaneous Irritation with DIFFERIN® Cream from Controlled Clinical Studies (N=285) topical dose exhibited no fetotoxicity and only minimal increases in super- said that they sometimes did, and 1% said Rx Only BRIEF SUMMARY numerary ribs in rats. There are no adequate and well-controlled studies in None Mild Moderate Severe that they rarely or never did. In contrast, For topical use only. Not for ophthalmic, oral, or intravaginal use. pregnant women. Adapalene should be used during pregnancy only if the Erythema 52% (148) 38% (108) 10% (28) <1% (1) ® potential benefit justifies the potential risk to the fetus. 75% of family physicians said that they rou- INDICATIONS AND USAGE: DIFFERIN Cream is indicated for the topical Scaling 58% (166) 35% (100) 6% (18) <1% (1) treatment of acne vulgaris. Nursing Mothers: It is not known whether this drug is excreted in human Dryness 48% (136) 42% (121) 9% (26) <1% (2) tinely recommended the vaccine for their CONTRAINDICATIONS: DIFFERIN® Cream should not be administered to milk. Because many drugs are excreted in human milk, caution should Pruritus (persistent) 74% (211) 21% (61) 4% (12) <1% (1) ® individuals who are hypersensitive to adapalene or any of the components be exercised when DIFFERIN Gel is administered to a nursing woman. 11- to 12-year-old patients, 12% said they Burning/Stinging 71% (202) 24% (69) 4% (12) <1% (2) Pediatric Use: Safety and effectiveness in pediatric patients below the in the cream vehicle. (persistent) sometimes did, and 13% said that they PRECAUTIONS: General: If a reaction suggesting sensitivity or chemical age of 12 have not been established. Other reported local cutaneous adverse events in patients who used irritation occurs, use of the medication should be discontinued. Exposure to ADVERSE REACTIONS: Some adverse effects such as erythema, scaling, rarely or never did. These differences were DIFFERIN® Cream once daily included: sunburn (2%), skin discomfort- sunlight, including sunlamps, should be minimized during use of adapalene. dryness, pruritus, and burning will occur in 10-40% of patients. Pruritus burning and stinging (1%) and skin irritation (1%). Events occurring in statistically significant. Patients who normally experience high levels of sun exposure, and those or burning immediately after application also occurs in approximately less than 1% of patients treated with DIFFERIN® Cream included: acne flare, with inherent sensitivity to sun, should be warned to exercise caution. 20% of patients. The following additional adverse experiences were dermatitis and contact dermatitis, eyelid edema, conjunctivitis, erythema, The results were similar regarding rec- Use of sunscreen products and protective clothing over treated areas reported in approximately 1% or less of patients: skin irritation, pruritus, skin discoloration, rash, and eczema. is recommended when exposure cannot be avoided. Weather extremes, burning/stinging, erythema, sunburn, and acne flares. These are most ommendations ® such as wind or cold, also may be irritating to patients under treatment OVERDOSAGE: DIFFERIN Cream is intended for cutaneous use only. If commonly seen during the first month of therapy and decrease in A full 96% of for Tdap boost- with adapalene. the medication is applied excessively, no more rapid or better results frequency and severity thereafter. All adverse effects with use of will be obtained and marked redness, scaling, or skin discomfort may ® Avoid contact with the eyes, lips, angles of the nose, and mucous DIFFERIN Gel during clinical trials were reversible upon discontinuation ers for 13- to 18- occur. The acute oral toxicity of DIFFERIN® Cream in mice and rats is pediatricians said membranes. The product should not be applied to cuts, abrasions, of therapy. greater than 10 mL/kg. Chronic ingestion of the drug may lead to the ® year-old pa- eczematous or sunburned skin. As with other retinoids, use of “waxing” OVERDOSAGE: DIFFERIN Gel is intended for cutaneous use only. If the same side effects as those associated with excessive oral intake of as a depilatory method should be avoided on skin treated with adapalene. medication is applied excessively, no more rapid or better results will be they routinely tients without a Vitamin A. Information for Patients: Patients using DIFFERIN® Cream should obtained and marked redness, peeling, or discomfort may occur. The ® previous Td receive the following information and instructions: acute oral toxicity of DIFFERIN Gel in mice and rats is greater than 10 recommend Marketed by: Manufactured by: mL/kg. Chronic ingestion of the drug may lead to the same side effects 1. This medication is to be used only as directed by the physician. booster. Among GALDERMA LABORATORIES, L.P. DPT Laboratories, Ltd. as those associated with excessive oral intake of Vitamin A. 2. It is for external use only. Fort Worth, Texas 76177 USA San Antonio, Texas 78215 USA giving Tdap to pediatricians, GALDERMA is a registered trademark. 3. Avoid contact with the eyes, lips, angles of the nose, and mucous Marketed by: Manufactured by: 96% routinely membranes. www.differin.com GALDERMA LABORATORIES, L.P. DPT Laboratories, Ltd. 11- to 12-year- 4. Cleanse area with a mild or soapless cleanser before applying this 325069-0805 Fort Worth, Texas 76177 USA San Antonio, Texas 78215 USA recommended medication. Revised: August 2005 GALDERMA is a registered trademark. olds; 3% said this booster, 3% 5. Moisturizers may be used if necessary; however, products containing 325034-0903 Revised: September 2003 alpha hydroxy or glycolic acids should be avoided. they sometimes sometimes did, 6. Exposure of the eye to this medication may result in reactions such as DIFFERIN ® (adapalene gel) Gel, 0.1% and 1% rarely swelling, conjunctivitis, and eye irritation. 7. This medication should not be applied to cuts, abrasions, eczematous or Rx Only BRIEF SUMMARY did so; 1% said or never did. INDICATIONS AND USAGE: DIFFERIN® Gel is indicated for the topical sunburned skin. References: 1. Zaenglein AL, Thiboutot DM. Expert committee Among family 8. Wax epilation should not be performed on treated skin due to the potential treatment of acne vulgaris. recommendations for acne management. Pediatrics. 2006; rarely or never. for skin erosions. CONTRAINDICATIONS: DIFFERIN® Gel should not be administered to 118:1188-1199. 2. Gollnick H, Cunliffe W, Berson D, et al. physicians, 80% individuals who are hypersensitive to adapalene or any of the components Management of acne: a report from a global alliance to improve 9. During the early weeks of therapy, an apparent exacerbation of acne may J Am Acad Dermatol in the vehicle gel. outcomes in acne. 2003;49:S1-S38. routinely recommended the booster, 10% occur. This is due to the action of this medication on previously unseen 3. Pariser DM, Thiboutot DM, Clark SD, Jones TM, Liu Y, Graeber ® lesions and should not be considered a reason to discontinue therapy. WARNINGS: Use of DIFFERIN Gel should be discontinued if hypersensitivity M; Adapalene Study Group. The efficacy and safety of adapalene gel sometimes did, and 10% rarely or never did. Overall clinical benefit may be noticed after two weeks of therapy, but at to any of the ingredients is noted. Patients with sunburn should be 0.3% in the treatment of acne vulgaris: A randomized, multicenter, Once again, the differences were statisti- least eight weeks are required to obtain consistent beneficial effects.
Load more

Recommended publications
  • Azelaic Acid
    Azelaic Acid (FINACEA) Topical Foam 15% National Drug Monograph August 2016 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a focused drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Azelaic acid is a naturally occurring C9-dicarboxylic acid that is found in plants Action (such as whole grain cereals), animals and humans. Azelaic acid has antiinflammatory, antioxidative and antikeratinizing effects. In rosacea skin, azelaic acid decreases cathelicidin levels and kallikrein 5 (KLK5) activity and possibly inhibits toll-like receptor 2 (TLR2) expression.1 A 15% gel formulation has been marketed for rosacea, and 20% cream has been available for acne vulgaris. The newer foam formulation consists of an oil- in-water emulsion and was designed to have a higher lipid content than the gel for dry and sensitive skin. Indication(s) Under Review Topical treatment of inflammatory papules and pustules of mild to moderate in This Document rosacea. Dosage Form(s) Under Foam, 15% Review REMS REMS No REMS Postmarketing Requirements See Other Considerations for additional REMS information Pregnancy Rating Category B Executive Summary Efficacy There have been no head-to-head trials comparing the foam and gel formulations of azelaic acid in terms of safety, tolerability and efficacy in the treatment of papulopustular (PP) rosacea.. In two major randomized clinical trials, azelaic acid foam produced small benefits over vehicle foam in achieving Investigator’s Global Assessment (IGA) treatment success (NNTs of 9.2 and 11.5) and in reducing inflammatory lesion counts.
    [Show full text]
  • Skin - Sulfa*Derm Sulfaderm Or Sulfa*Derm - Helps Promote Healthy Skin Function
    Skin - Sulfa*Derm Sulfaderm or Sulfa*Derm - Helps promote Healthy skin Function. Has been shown to help clear up most Acne in 24 hours, Bacterial infections, Rashes, Bed Sores, Dermatitis, Eczema, Fungus/Yeast, Psoriasis type problems, Ring Worm and Wounds that won't heal. HISTORY OF SULFUR Harnessing the power of volcanos, our cutting edge formula is considered a breakthrough for the treatment of acne. Sulfa*Derm has been shown to clear up acne in one day. The active ingredient sulfur from volcanic ash destroys bacteria quickly. The Zinc Oxide combats rashes. Tea Tree Oil is a well known antiseptic and anti-fungal, while the Aloe Vera re-nourishes the skin. Vitamin E is used as the base instead of oils that clog up the skin. Sulfa*Derm is probably the best acne and everything else cream that has ever been made. When treating skin problems it is recommended to detoxify your liver. Sulfur is a yellow mineral that quite often occurs in nature in powder form. It can, under pressure bond to water, as in mineral springs or mix into the earth, as in mud baths. Normally sulfur is expunged from under the ground through the craters of venting volcanoes, where it is spread around in chunky blocks. Sulfur has been around for a long time. Native Polynesians claim to have cured a variety of infections in their hot sulfur mineral springs. Russian mud treatments, high in sulfur, have been used for centuries as a reputed therapy for arthritis. California's Napa Valley, specifically the city called Sulfur Springs, was the health spa for the wealthy until the early 1900's.
    [Show full text]
  • Enhanced Catalytic Ozonation of Ibuprofen Using a 3D Structured
    www.nature.com/scientificreports OPEN Enhanced catalytic ozonation of ibuprofen using a 3D structured catalyst with MnO2 nanosheets on carbon microfbers Guhankumar Ponnusamy1, Hajar Farzaneh2, Yongfeng Tong1, Jenny Lawler1, Zhaoyang Liu1* & Jayaprakash Saththasivam1* Heterogeneous catalytic ozonation is an efective approach to degrade refractory organic pollutants in water. However, ozonation catalysts with combined merits of high activity, good reusability and low cost for practical industrial applications are still rare. This study aims to develop an efcient, stable and economic ozonation catalyst for the degradation of Ibuprofen, a pharmaceutical compound frequently detected as a refractory pollutant in treated wastewaters. The novel three-dimensional network-structured catalyst, comprising of δ-MnO2 nanosheets grown on woven carbon microfbers (MnO2 nanosheets/carbon microfber), was synthesized via a facile hydrothermal approach. Catalytic ozonation performance of Ibuprofen removal in water using the new catalyst proves a signifcant enhancement, where Ibuprofen removal efciency of close to 90% was achieved with a catalyst loading of 1% (w/v). In contrast, conventional ozonation was only able to achieve 65% removal efciency under the same operating condition. The enhanced performance with the new catalyst could be attributed to its signifcantly increased available surface active sites and improved mass transfer of reaction media, as a result of the special surface and structure properties of this new three- dimensional network-structured catalyst. Moreover, the new catalyst displays excellent stability and reusability for ibuprofen degradation over successive reaction cycles. The facile synthesis method and low-cost materials render the new catalyst high potential for industrial scaling up. With the combined advantages of high efciency, high stability, and low cost, this study sheds new light for industrial applications of ozonation catalysts.
    [Show full text]
  • Precipitated Sulfur: Summary Report
    Precipitated Sulfur: Summary Report Item Type Report Authors Yuen, Melissa V.; Gianturco, Stephanie L.; Pavlech, Laura L.; Storm, Kathena D.; Yoon, SeJeong; Mattingly, Ashlee N. Publication Date 2020-02 Keywords Precipitated sulfur; Compounding; Food, Drug, and Cosmetic Act, Section 503B; Food and Drug Administration; Outsourcing facility; Drug compounding; Legislation, Drug; United States Food and Drug Administration Rights Attribution-NoDerivatives 4.0 International Download date 02/10/2021 22:32:18 Item License http://creativecommons.org/licenses/by-nd/4.0/ Link to Item http://hdl.handle.net/10713/12274 Summary Report Precipitated Sulfur Prepared for: Food and Drug Administration Clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: 2U01FD005946 Prepared by: University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) University of Maryland School of Pharmacy February 2020 This report was supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award (U01FD005946) totaling $2,342,364, with 100 percent funded by the FDA/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, the FDA/HHS or the U.S. Government. 1 Table of Contents REVIEW OF NOMINATIONS ................................................................................................... 4 METHODOLOGY ...................................................................................................................
    [Show full text]
  • Hirsutism Joshua C
    Review Hirsutism Joshua C. Berkowitz, BA; Adeel Kahtri, MD; Rao N. Saladi, MD; Dovid Herskowitz, BA; Joshua L. Fox, MD Hirsutism is defined as the development of a malelike pattern of excess hair especially in women. Hirsut- ism often results from raised androgen levels in the body and may indicate the existence of a serious underlying endocrine condition, such as polycystic ovary syndrome (PCOS). Treatment of hirsutism may require both medical and cosmetic actions. Medical therapy aims to counteract any suspected hormonal imbalance and can include administration of oral contraceptives and antiandrogens. Cosmetic treat- ment directly addresses excess hair and seeks to either remove the hair or diminish its appearance. Cos- metic options range from conventional methods, such as shaving and waxing, to modern techniques, such as laserCOS photoepilation. DERM irsutism refers to the growth of coarse that occurs despite normal androgen levels and normal terminal hair in females that follows a ovulatory function. malelike pattern, most commonly in the To comprehend the underlying mechanism of hirsut- upper lip area, beard area, abdomen, or ism, it is necessary to understand the physiology of hair chest. The amount of hair that is consid- growth. There are 2 types of hair: fine, nonpigmented Hered Donormal is subjective. In someNot cultures, women are vellus hairCopy and coarse, pigmented terminal hair. Both of disturbed by even a small amount of excess hair, while these hair types originate from the same pilosebaceous in other cultures, larger amounts may be tolerated and unit in the skin. Development of terminal hair mainly considered normal. The perception of excess hair has an is dependent on stimulation of the pilosebaceous unit associated psychosocial stigma that affects the lives of by androgens.
    [Show full text]
  • Food and Drug Administration, HHS § 333.350
    Food and Drug Administration, HHS § 333.350 (b) References in this subpart to reg- § 333.350 Labeling of acne drug prod- ulatory sections of the Code of Federal ucts. Regulations are to chapter I of title 21 (a) Statement of identity. The labeling unless otherwise noted. of the product contains the established name of the drug, if any, and identifies § 333.303 Definitions. the product as an ‘‘acne medication,’’ As used in this subpart: ‘‘acne treatment,’’ ‘‘acne medication’’ (a) Acne. A disease involving the oil (insert dosage form, e.g., ‘‘cream,’’ glands and hair follicles of the skin ‘‘gel,’’ ‘‘lotion,’’ or ‘‘ointment’’), or which is manifested by blackheads, ‘‘acne treatment’’ (insert dosage form, whiteheads, acne pimples, and acne e.g., ‘‘cream,’’ ‘‘gel,’’ ‘‘lotion,’’ or blemishes. ‘‘ointment’’). (b) Acne blemish. A flaw in the skin (b) Indications. The labeling of the resulting from acne. product states, under the heading ‘‘In- (c) Acne drug product. A drug product dications,’’ the phrase listed in para- used to reduce the number of acne graph (b)(1) of this section and may blemishes, acne pimples, blackheads, contain any of the additional phrases and whiteheads. listed in paragraph (b)(2) of this sec- (d) Acne pimple. A small, prominent, tion. Other truthful and nonmisleading inflamed elevation of the skin result- statements, describing only the indica- ing from acne. tions for use that have been established (e) Blackhead. A condition of the skin and listed in paragraph (b) of this sec- that occurs in acne and is character- tion, may also be used, as provided in ized by a black tip.
    [Show full text]
  • Minocycline-Induced Pigmentation Mimicking Persistent Ecchymosis
    CONTINUING MEDICAL EDUCATION Minocycline-Induced Pigmentation Mimicking Persistent Ecchymosis Sherry Youssef, MD, MPH, MS; Kathy Kim Langevin, MD, MPH; Lorraine C. Young, MD RELEASE DATE: July 2009 TERMINATION DATE: July 2010 The estimated time to complete this activity is 1 hour. GOAL To understand minocycline-induced pigmentation to better manage patients with the condition LEARNING OBJECTIVES Upon completion of this activity, you will be able to: 1. Distinguish the 3 common patterns of pigmentation based on clinical characteristics. 2. Recognize histologic findings of pigmentation. 3. Discuss the role of the duration and cumulative dose of minocycline on the incidence of pigmentation. INTENDED AUDIENCE This CME activity is designed for dermatologists and general practitioners. CME Test and Instructions on page 40. This article has been peer reviewed and ap- HealthCom, Inc. Albert Einstein College of Medicine proved by Ranon Ephraim Mann, MD, Assistant is accredited by the ACCME to provide continuing Professor, Department of Medicine (Dermatology), medical education for physicians. Albert Einstein College of Medicine. Review date: Albert Einstein College of Medicine designates June 2009. this educational activity for a maximum of 1 AMA This activity has been planned and implemented PRA Category 1 Credit TM. Physicians should only in accordance with the Essential Areas and Policies claim credit commensurate with the extent of their of the Accreditation Council for Continuing participation in the activity. Medical Education through the joint sponsorship of This activity has been planned and produced in Albert Einstein College of Medicine and Quadrant accordance with ACCME Essentials. Drs. Youssef and Young report no conflict of interest. Dr.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • • the PDL Is a List of Over 100 Therapeutic Classes Reviewed by the Pharmaceutical & Therapeutics (P&T) Committee
    Louisiana Medicaid Preferred Drug List (PDL)/Non-Preferred Drug List (NPDL) http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf • The PDL is a list of over 100 therapeutic classes reviewed by the Pharmaceutical & Therapeutics (P&T) committee. In addition, there are medications and/or classes of medications that are not reviewed by the committee. Unless there is a clinical pre-authorization requirement for the entire class (as noted on the last page of the PDL) these medications will continue to be covered without prior authorization. Examples: spironolactone, hydrochlorothiazide, amoxicillin suspension • There is a mandatory generic substitution unless the brand is preferred and the generic is non-preferred. When the brand is preferred and the generic is non-preferred, no special notations are required by the prescriber and the pharmacist enters “9” in the DAW field 408-D8. • When the brand is non-preferred and the prescriber has determined it to be medically necessary, “Brand medically necessary” or “Brand necessary” must be written on the prescription in the prescriber’s handwriting or via an electronic prescription and the pharmacist enters “1” in the DAW field 408-D8. For more information, please refer to the following policy: https://www.lamedicaid.com/provweb1/Providermanuals/manuals/PHARMACY/PHARMACY.pdf • To locate any medication on this list, you may use the keyboard shortcut CTRL + F to search. • New medications that enter the marketplace in classes reviewed by P&T committee will be considered non-preferred requiring prior authorization until the next P&T committee meeting. Please refer to the following criteria: New Drugs Introduced into the Market / Non-Preferred • The PDL is arranged by therapeutic class with an item number and may contain a subset of medications under each therapeutic class.
    [Show full text]
  • Microdermabrasion
    Advanced Dermatology Care Advanced Esthetics Microdermabrasion About Microdermabrasion: Microdermabrasion is helpful for reducing the appearance of fine lines/wrinkles, dull, dry, rough or sun-damaged skin; it can also help treat acne, and even soften some superficial scars including stretch marks. Dead skin cells that have become sticky with maturity and contribute to a thicker, dull complexion are removed with this procedure, giving the skin a fresh, more youthful appearance. A series of microdermabrasion treatments can also help firm the skin; it uses a vacuum which stimulates blood flow and fibroblasts in the skin, thus stimulating collagen and elastin. Pores are refined, and skin feels remarkably smoother as the dead skin cells and debris are swept away. Advanced Esthetics has two microdermabrasion methods available. These treatments both produce equal results, but personal preference may guide your choice. MegaPeel Microdermabrasion: This method gently blasts small particles of aluminum oxide over the skin’s epidermis to help remove dead skin cells on the skin’s surface. The MegaPeel medical research shows biopsy-proven increases in collagen and elastin, and smoother, healthier skin. DermaSweep Microdermabrasion: Rather than using crystals, this method uses patented bristle technology for exfoliation. To further address each patient’s unique skin care needs, a variety of skin-specific topical solutions can be applied immediately after a microdermabrasion treatment. These topical solutions are tailored to each patient’s specific
    [Show full text]
  • Acne Agents, Topical (1) POS Abbreviations
    Acne Agents, Topical (1) Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to any medication, whether or not it is listed in the Preferred Drug List / Non- Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications. POS Abbreviations AL – Age Limit DD – Drug-Drug Interaction MD – Maximum Dose Limit TD – Therapeutic Duplication BH – Behavioral Health Clinical DS – Maximum Days’ Supply PR – Enrollment in a Physician- UN – Drug Use Not Warranted Authorization for Children Allowed Supervised Program Required Younger than 7 Years of Age BY – Diagnosis Codes Bypass DT – Duration of Therapy Limit PU – Prior Use of Other X – Prescriber Must Have ‘X’ Some Requirements Medication is Required DEA Number CL – Additional Clinical DX – Diagnosis Code QL – Quantity Limit YQ – Yearly Quantity Limit Information is Required Requirement CU – Concurrent Use with Other ER – Early Refill RX – Specific Prescription Medication is Restricted Requirement Pharmacy Prior Authorization Phone Numbers for MCOs and FFS Aetna Better Health of Louisiana 1-855-242-0802 AmeriHealth Caritas Louisiana 1-800-684-5502 Fee-for-Service (FFS) Louisiana Legacy Medicaid 1-866-730-4357 Healthy Blue 1-844-521-6942 Louisiana Healthcare Connections 1-888-929-3790 UnitedHealthcare 1-800-310-6826 1 Acne Agents, Topical (1) POS Edits AL – All agents are limited to use in recipients who are younger than 21 years of age when used for acne.
    [Show full text]
  • Sulfur Deprivation Modulates Salicylic Acid Responses Via Nonexpressor of Pathogenesis-Related Gene 1 in Arabidopsis Thaliana
    plants Article Sulfur Deprivation Modulates Salicylic Acid Responses via Nonexpressor of Pathogenesis-Related Gene 1 in Arabidopsis thaliana Steven Criollo-Arteaga 1 , Sofia Moya-Jimenez 1, Martin Jimenez-Meza 1, Victor Gonzalez-Vera 1, Jessica Gordon-Nunez 1, Sol Llerena-Llerena 1, Dario X. Ramirez-Villacis 1,2,3, Pieter van ‘t Hof 2,4,5 and Antonio Leon-Reyes 1,2,3,4,* 1 Laboratorio de Biotecnología Agrícola y de Alimentos, Ingeniería en Agronomía, Colegio de Ciencias e Ingenierías, Universidad San Francisco de Quito USFQ, Diego de Robles y Vía Interoceánica, Quito 17-1200-841, Ecuador; [email protected] (S.C.-A.); moyajimenezsofi[email protected] (S.M.-J.); [email protected] (M.J.-M.); [email protected] (V.G.-V.); [email protected] (J.G.-N.); [email protected] (S.L.-L.); [email protected] (D.X.R.-V.) 2 Colegio de Ciencias Biológicas y Ambientales, Instituto de Microbiología, Universidad San Francisco de Quito USFQ, Diego de Robles y Vía Interoceánica, Quito 17-1200-841, Ecuador; [email protected] 3 Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3280, USA 4 Colegio de Ciencias Biológicas y Ambientales, Instituto BIOSFERA, Universidad San Francisco de Quito USFQ, Diego de Robles y Vía Interoceánica, Quito 17-1200-841, Ecuador 5 Colegio de Ciencias Biológicas y Ambientales, Universidad San Francisco de Quito USFQ, Diego de Robles y Citation: Criollo-Arteaga, S.; Vía Interoceánica, Quito 17-1200-841, Ecuador Moya-Jimenez, S.; Jimenez-Meza, M.; * Correspondence: [email protected] Gonzalez-Vera, V.; Gordon-Nunez, J.; Llerena-Llerena, S.; Ramirez-Villacis, Abstract: Mineral nutrients are essential for plant growth and reproduction, yet only a few studies D.X.; van ‘t Hof, P.; Leon-Reyes, A.
    [Show full text]